- •Preface
- •Contents
- •1 Extracellular and Intracellular Signaling – a New Approach to Diseases and Treatments
- •1.1 Introduction
- •1.1.1 Linear Model of Drug Receptor Interactions
- •1.1.2 Matrix Model of Drug Receptor Interactions
- •1.2 Experimental Approaches to Disease Treatment
- •1.3 Adipokines and Disease Causation
- •1.4 Questions in Disease Treatment
- •1.5 Toxic Lifestyles and Disease Treatment
- •References
- •2.1 Introduction
- •2.2 Heterogeneity of Adipose Tissue Composition in Relation to Adipokine and Cytokine Secretion
- •2.3 Feedback between FA and the Adipocyte
- •2.6 Metabolic Programming of Autocrine Signaling in Adipose Tissue
- •2.8 Cell Heterogeneity in the Pancreatic Islet
- •2.16 Concluding Remarks
- •Acknowledgements
- •References
- •3 One Receptor for Multiple Pathways: Focus on Leptin Signaling
- •3.1 Leptin
- •3.2 Leptin Receptors
- •3.3 Leptin Receptor Signaling
- •3.3.4 AMPK
- •3.3.5 SOCS3
- •3.4 Leptin Receptor Interactions
- •3.4.1 Apolipoprotein D
- •3.4.2 Sorting Nexin Molecules
- •3.4.3 Diacylglycerol Kinase Zeta
- •3.4.4 Apolipoprotein J
- •References
- •4.1 Introduction
- •4.2 Leptin: A Brief Introduction
- •4.3 Expression of Leptin Receptors in Cardiovascular Tissues
- •4.6 Post Receptor Leptin Signaling
- •4.6.2 Mitogen Activated Protein Kinase Stimulation
- •4.7 Adiponectin
- •4.7.1 Adiponectin and Cardiovascular Disease
- •4.7.2 Adiponectin and Experimental Cardiac Hypertrophy
- •4.8 Resistin
- •4.8.1 Cardiac Actions of Resistin
- •4.8.1.1 Experimental Studies on the Cardiac Actions of Resistin
- •4.9 Apelin
- •4.9.1 Apelin and Heart Disease
- •4.10 Visfatin
- •4.11 Other Novel Adipokines
- •4.12 Summary, Conclusions and Future Directions
- •Acknowledgements
- •References
- •5 Regulation of Muscle Proteostasis via Extramuscular Signals
- •5.1 Basic Protein Synthesis
- •5.2.1 Hormones
- •5.2.1.1 Mechanisms of Action: Glucocorticoids
- •5.2.1.2 Mechanisms of Action: TH (T3)
- •5.2.1.3 Mechanisms of Action: Testosterone
- •5.2.1.4 Mechanisms of Action: Epinephrine
- •5.2.2 Local Factors (Autocrine/Paracrine)
- •5.2.2.1 Mechanisms of Action: Insulin/IGF Spliceoforms
- •5.2.2.2 Mechanisms of Action: Fibroblast Growth Factor (FGF)
- •5.2.2.3 Mechanisms of Action: Myostatin
- •5.2.2.4 Mechanisms of Action: Cytokines
- •5.2.2.5 Mechanisms of Action: Neurotrophins
- •5.2.2.7 Mechanisms of Action: Extracellular Matrix
- •5.2.2.8 Mechanisms of Action: Amino Acids (AA)
- •5.3 Regulation of Muscle Proteostasis in Humans
- •5.3.1 Nutrients as Regulators of Muscle Proteostasis in Man
- •5.3.2 Muscular Activity (i.e. Exercise) as a Regulator of Muscle Proteostasis
- •5.4 Conditions Associated with Alterations in Muscle Proteostasis in Humans
- •5.4.2 Disuse Atrophy
- •5.4.3 Sepsis
- •5.4.4 Burns
- •5.4.5 Cancer Cachexia
- •References
- •6 Contact Normalization: Mechanisms and Pathways to Biomarkers and Chemotherapeutic Targets
- •6.1 Introduction
- •6.2 Contact Normalization
- •6.3 Cadherins
- •6.4 Gap Junctions
- •6.5 Contact Normalization and Tumor Suppressors
- •6.6 Contact Normalization and Tumor Promoters
- •6.7 Conclusions
- •References
- •7.1 Introduction
- •7.2 Background on Migraine Headache
- •7.3 Migraine and Neuropathic Pain
- •7.4 Role of Astrocytes in Pain
- •7.5 Adipokines and Related Extracellular Signalling
- •7.6 The Future of Signaling Research to Migraine
- •Acknowledgements
- •References
- •8.1 Alzheimer’s Disease
- •8.1.2 Target for AD Therapy
- •8.2 AD and Metabolic Dysfunction
- •8.2.1 Impaired Glucose Metabolism
- •8.2.2 Lipid Disorders
- •8.2.3 Obesity
- •8.3 Adipokines
- •8.3.1 Leptin
- •8.3.2 Adiponectin
- •8.3.3 Resistin
- •8.3.4 Visfatin
- •8.3.5 Plasminogen Activator Inhibitor
- •8.3.6 Interleukin-6
- •8.4 Conclusions
- •References
- •9.1 Introduction
- •9.1.1 Structure and Function of Astrocytes
- •9.1.1.1 Morphology
- •9.1.1.2 Astrocyte Functions
- •9.1.2 Responses of Astrocytes to Injury
- •9.1.2.1 Reactive Astrocytosis
- •9.1.2.2 Cell Swelling
- •9.1.2.3 Alzheimer Type II Astrocytosis
- •9.2 Intracellular Signaling System in Reactive Astrocytes
- •9.2.1 Oxidative/Nitrosative Stress (ONS)
- •9.2.2 Protein Kinase C (PKC)
- •9.2.5 Signal Transducer and Activator of Transcription 3 (STAT3)
- •9.3 Signaling Systems in Astrocyte Swelling
- •9.3.1 Oxidative/Nitrosative Stress (ONS)
- •9.3.2 Cytokines
- •9.3.3 Protein Kinase C (PKC)
- •9.3.5 Protein Kinase G (PKG)
- •9.3.7 Signal Transducer and Activator of Transcription 3 (STAT3)
- •9.3.10 Ion Channels/Transporters/Exchangers
- •9.4 Conclusions and Perspectives
- •Acknowledgements
- •References
- •10.1 Adipokines, Toxic Lipids and the Aging Brain
- •10.1.1 Toxic Lifestyles, Adipokines and Toxic Lipids
- •10.1.2 Ceramide Toxicity in the Brain
- •10.3 Oxygen Radicals, Hydrogen Peroxide and Cell Death
- •10.4 Gene Transcription and DNA Damage
- •10.5 Conclusions
- •References
- •11.1 Introduction
- •11.2 Cellular Signaling
- •11.2.1 Types of Signaling
- •11.2.2 Membrane Proteins in Signaling
- •11.3 G Protein-Coupled Receptors
- •11.3.1 Structure of GPCRs
- •11.3.1.1 Structure Determination
- •11.3.1.2 Structural Diversity of Current GPCR Structures
- •11.3.1.3 Prediction of GPCR Structure and Ligand Binding
- •11.3.2 GPCR Activation: Conformation Driven Functional Selectivity
- •11.3.2.2 Ligand or Mutation Stabilized Ensemble of GPCR Conformations
- •11.3.2.4 GPCR Dimers and Interaction with Other Proteins
- •11.3.3 Functional Control of GPCRs by Ligands
- •11.3.3.1 Biased Agonism
- •11.3.3.2 Allosteric Ligands and Signal Modulation
- •11.3.4 Challenges in GPCR Targeted Drug Design
- •11.4 Summary and Looking Ahead
- •Acknowledgements
- •References
- •12.1 Introduction
- •12.5.1 Anthocyanins
- •12.5.2 Gallates
- •12.5.3 Quercetin
- •12.5.5 Piperine
- •12.5.6 Gingerol
- •12.5.7 Curcumin
- •12.5.8 Guggulsterone
- •12.6.1 Phytanic Acid
- •12.6.2 Dehydroabietic Acid
- •12.6.3 Geraniol
- •12.7 Agonists of LXR that Reciprocally Inhibit NF-jB
- •12.7.1 Stigmasterol
- •12.7.3 Ergosterol
- •12.8 Conclusion
- •References
- •13.1 Introduction
- •13.2 Selective Dopaminergic Neuronal Death
- •13.3 Signaling Pathways Involved in Selective Dopaminergic Neuronal Death
- •13.3.1 Initiators and Signaling Molecules
- •13.3.1.1 Response to Oxidative and Nitrosative Stress
- •13.3.1.2 Response to Altered Proteostasis
- •13.3.1.3 Response to Glutamate
- •13.3.1.4 Other Initiators
- •13.3.2 Signal Transducers, Intracellular Messengers and Upstream Elements
- •13.3.2.2 Small GTPases
- •13.3.3 Intracellular Signaling Cascades
- •13.3.3.1 Mitogen Activated Protein Kinases (MAPK) Pathway
- •13.3.3.2 PI3K/Akt Pathway
- •13.3.3.4 Unfolded Protein Response (UPR)
- •13.3.4 Potentially Involved Intracellular Signaling Components
- •13.3.4.3 PINK1
- •13.3.5.2 Dopamine Metabolism
- •13.3.5.3 Cell Cycle
- •13.3.5.4 Autophagy
- •13.3.5.5 Apoptosis
- •13.4 Conclusions
- •References
- •Subject Index
Phytochemicals as Modulators of Signaling in Inflammation |
239 |
N
O
O
O
Figure 12.6 Piperine.
O OH
HO
O
Figure 12.7 Gingerol.
12.5.6Gingerol
Gingerol is another phytochemical, known to inhibit NF-kB-mediated inflammation (Figure 12.7). It is the pungent constituent of ginger. Gingerol has also been found to inhibit IkB kinase activity.32 In this study, macrophages (RAW 264 cells) were stimulated by LPS, which activated the cells and initiated an inflammatory cascade with NF-kB stimulation. It was found that an 80-mM concentration of gingerol can inhibit 70% of the NF-kB activation by LPS. The bioavailability of gingerol is not high, with peak concentrations of metabolites being 0.1 mg/ml to 1.7 mg/ml in human plasma after a 1 g dose.33
12.5.7Curcumin
Curcumin is the main ingredient found in the curry spice tumeric (Figure 12.8). Curcumin has been found to inhibit NF-kB. One study found that 10–20 mM amounts of curcumin can inhibit NF-kB in MyD88 and RAW264.7 cells activated by LPS.34 This was shown to occur through blocking the dimerization of TLR-4 and by inhibiting IkB kinase. Curcumin inhibits numerous inflammatory pathways upstream and downstream of NF-kB, such as mitogenic pathways, AP-1
transcription and expression of COX-2, anti-apoptotic proteins and growth factors.35,36 Curcumin was confirmed to inhibit IkB kinase activity.36 The con-
centration needed to inhibit NF-kB from IL-1 activation in U937 cells was 50 mM. However, curcumin has very poor bioavailability. The concentrations found in human plasma were 0.4–3.6 mM after the ingestion of 4–8 g of
240 Chapter 12
curcumin.37 The bioavailability is greatly improved with the addition of piperine.
12.5.8Guggulsterone
Guggulsterone has been used for centuries in Ayurvedic medicine for its anti-inflammatory activity in arthritis, cardiovascular disease, obesity and bone fractures38 (Figure 12.9). It is found in the guggul plant in northern India. Guggulsterone has been found to inhibit NF-kB activation by RANKL (TNFa cytokine family) in RAW-269.7 cells.38 This study demonstrated that guggulsterone was a direct inhibitor of IkB kinase. The doses found to inhibit NF-kB entirely were 10 mM in this cell system. Another study similarly found that NF-kB activation by IL- 1b could also be abolished at 10 mM concentrations of guggulsterone in fibroblastlike synoviocytes, a cell model for arthritis,39 by blocking the degradation of IkBa.
It is known that mM amounts of guggulsterone inhibit inflammation in vivo, and guggulsterone has numerous beneficial e ects in vivo,40 such as in the cardiovascular system in humans. However, there are few data as to the bioavailability of this agent.
O |
OH |
O |
O |
HO |
OH |
Figure 12.8 Curcumin.
H O
H H
O
H O
H H
O
Figure 12.9 E- and Z-Guggulsterone.
Phytochemicals as Modulators of Signaling in Inflammation |
241 |
12.6Agonists of PPARc that Reciprocally Inhibit NF-jB
In general, many of the natural agonists of PPARg are analogs of fatty acids, lipid molecules, cholesterol and other terpenoids.41 Terpenoids can be found in eucalyptus, cinnamon, cloves, ginger, citral, menthol, camphor and many plants. The following are a few examples of common natural product PPARg agonists.
12.6.1Phytanic Acid
Phytanic acid is an example of a terpenoid derived from chlorophyll in plant extracts. It is a derivative of the phytol side chain of chlorophyll. In one study, phytanic acid (Figure 12.10) was able to stimulate PPARg activation in hepatocytes in a dose-dependent manner from 10–100 mM, in doses comparable to thiazolidinedione derivatives.42 Some of the original studies on phytanic acid demonstrated that human plasma contains mM levels of this compound.43
12.6.2Dehydroabietic Acid
Dehydroabietic acid is a diterpenoid found in pine tree resins. It is also a potent PPARg agonist.44 In this study, dehydroabietic acid (Figure 12.11) was found to inhibit the production of MCP-1, TNFa and NO in LPS-activated macrophages at a 40 mM concentration. However, no bioavailability data or toxicity studies are yet available for this agent.
O
OH
Figure 12.10 Phytanic acid.
H
HO O
Figure 12.11 Dehydroabietic acid.